{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:28:12Z","timestamp":1791336492731,"version":"4.3.1"},"reference-count":63,"publisher":"Oxford University Press (OUP)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,4,1]]},"DOI":"10.1093\/cid\/cix034","type":"journal-article","created":{"date-parts":[[2017,1,30]],"date-time":"2017-01-30T08:27:11Z","timestamp":1485764831000},"page":"972-980","source":"Crossref","is-referenced-by-count":174,"title":["The Use of Noncarbapenem \u03b2-Lactams for the Treatment of Extended-Spectrum \u03b2-Lactamase Infections"],"prefix":"10.1093","volume":"64","author":[{"given":"Pranita D.","family":"Tamma","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Pediatric Infectious Diseases, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Rodriguez-Ba\u0148o","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Microbiology, Instituto de Biomedicina de Sevilla\/Hospital Universitario Virgen Macarena\/Consejo Superior de Investigaciones Cient\u00edficas\/Universidad de Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,1,25]]},"reference":[{"key":"key\n\t\t\t\t20180306025457_CIT0001","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1128\/AAC.47.11.3554-3560.2003","article-title":"Extended-spectrum beta-lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV- and CTX-M-type beta-lactamases","volume":"47","author":"Paterson","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306025457_CIT0002","doi-asserted-by":"crossref","first-page":"e0154092","DOI":"10.1371\/journal.pone.0154092","article-title":"Characterization and clinical impact of bloodstream infection caused by carbapenemase-producing Enterobacteriaceae in seven Latin American countries","volume":"11","author":"Villegas","year":"2016","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180306025457_CIT0003","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ijantimicag.2016.01.008","article-title":"Epidemiology and antimicrobial susceptibility profiles of pathogens causing urinary tract infections in the Asia-Pacific region: results from the study for monitoring antimicrobial resistance trends (SMART), 2010\u20132013","volume":"47","author":"Jean","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20180306025457_CIT0004","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1128\/AAC.05186-14","article-title":"Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013","volume":"59","author":"Lob","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306025457_CIT0005","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/nyas.12023","article-title":"Proliferation and significance of clinically relevant \u03b2-lactamases","volume":"1277","author":"Bush","year":"2013","journal-title":"Ann N Y Acad Sci"},{"key":"key\n\t\t\t\t20180306025457_CIT0006","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/jac\/dks301","article-title":"Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum \u03b2-lactamases: a systematic review and meta-analysis","volume":"67","author":"Vardakas","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180306025457_CIT0007","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/420816","article-title":"Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases","volume":"39","author":"Paterson","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180306025457_CIT0008","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1017\/ice.2015.101","article-title":"Carbapenems versus piperacillin-tazobactam for bloodstream infections of nonurinary source caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae","volume":"36","author":"Ofer-Friedman","year":"2015","journal-title":"Infect Control Hosp Epidemiol"},{"key":"key\n\t\t\t\t20180306025457_CIT0009","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1128\/JCM.39.6.2206-2212.2001","article-title":"Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory","volume":"39","author":"Paterson","year":"2001","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20180306025457_CIT0010","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.diagmicrobio.2015.12.001","article-title":"In vitro activities and detection performances of cefmetazole and flomoxef for extended-spectrum \u03b2-lactamase and plasmid-mediated AmpC \u03b2-lactamase-producing Enterobacteriaceae","volume":"84","author":"Matsumura","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20180306025457_CIT0011","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/infdis\/159.5.1005","article-title":"In vivo selection of a cephamycin-resistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 beta-lactamase","volume":"159","author":"Pangon","year":"1989","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180306025457_CIT0012","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1128\/AAC.41.3.563","article-title":"Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the foss of an outer membrane protein","volume":"41","author":"Bradford","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306025457_CIT0013","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/jac\/dkl308","article-title":"In vivo selection of OmpK35-deficient mutant after cefuroxime therapy for primary liver abscess caused by Klebsiella pneumoniae","volume":"58","author":"Lee","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180306025457_CIT0014","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/jac\/dkm215","article-title":"Collateral damage of flomoxef therapy: in vivo development of porin deficiency and acquisition of blaDHA-1 leading to ertapenem resistance in a clinical isolate of Klebsiella pneumoniae producing CTX-M-3 and SHV-5 beta-lactamases","volume":"60","author":"Lee","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180306025457_CIT0015","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1093\/jac\/dkl381","article-title":"Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates","volume":"58","author":"Lee","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180306025457_CIT0016","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3109\/23744235.2015.1062133","article-title":"Cefoxitin as a carbapenem-sparing antibiotic for infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae","volume":"47","author":"Kern\u00e9is","year":"2015","journal-title":"Infect Dis (Lond)"},{"key":"key\n\t\t\t\t20180306025457_CIT0017","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.ijid.2012.09.010","article-title":"The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae","volume":"17","author":"Doi","year":"2013","journal-title":"Int J Infect Dis"},{"key":"key\n\t\t\t\t20180306025457_CIT0018","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/1471-2334-12-206","article-title":"Discrepancy between effects of carbapenems and flomoxef in treating nosocomial hemodialysis access-related bacteremia secondary to extended spectrum beta-lactamase producing Klebsiella pneumoniae in patients on maintenance hemodialysis","volume":"12","author":"Yang","year":"2012","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t20180306025457_CIT0019","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s10096-014-2094-y","article-title":"Alternatives to carbapenems for infections caused by ESBL-producing Enterobacteriaceae","volume":"33","author":"Pilmis","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20180306025457_CIT0020","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1128\/AAC.00701-15","article-title":"Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-\u03b2-lactamase-producing Escherichia coli bacteremia","volume":"59","author":"Matsumura","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306025457_CIT0021","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.1128\/AAC.02509-14","article-title":"Pharmacological study of cefoxitin as an alternative antibiotic therapy to carbapenems in treatment of urinary tract infections due to extended-spectrum-\u03b2-lactamase-producing Escherichia coli","volume":"58","author":"Guet-Revillet","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306025457_CIT0022","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2016","edition":"26th ed"},{"key":"key\n\t\t\t\t20180306025457_CIT0023","author":"European Union Committee on Antimicrobial Susceptibility Testing"},{"key":"key\n\t\t\t\t20180306025457_CIT0024","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1128\/JCM.00508-09","article-title":"Cephalosporin MIC distribution of extended-spectrum-{beta}-lactamase- and pAmpC-producing Escherichia coli and Klebsiella species","volume":"47","author":"Kohner","year":"2009","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20180306025457_CIT0025","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1128\/AAC.34.5.858","article-title":"Activities of beta-lactam antibiotics against Escherichia coli strains producing extended-spectrum beta-lactamases","volume":"34","author":"Jacoby","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306025457_CIT0026","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1128\/AAC.45.12.3548-3554.2001","article-title":"Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae","volume":"45","author":"Thomson","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306025457_CIT0027","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1046\/j.1198-743x.2001.x","article-title":"Effect of inoculum size on the antibacterial activity of cefpirome and cefepime against Klebsiella pneumoniae strains producing SHV extended-spectrum beta-lactamases","volume":"7","author":"Bedeni\u0107","year":"2001","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20180306025457_CIT0028","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1128\/AAC.45.4.1287-1291.2001","article-title":"In vitro and in vivo activities of amikacin, cefepime, amikacin plus cefepime, and imipenem against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain","volume":"45","author":"Szab\u00f3","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306025457_CIT0029","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1128\/AAC.35.6.1243","article-title":"Efficacy of different beta-lactams against an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain in the rat intra-abdominal abscess model","volume":"35","author":"Rice","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306025457_CIT0030","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1128\/AAC.41.5.1053","article-title":"Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum beta-lactamase-producing strain of Klebsiella pneumoniae","volume":"41","author":"Thauvin-Eliopoulos","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306025457_CIT0031","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1128\/AAC.39.5.1187","article-title":"In vitro activities of various beta-lactam antimicrobial agents against clinical isolates of Escherichia coli and Klebsiella spp. resistant to oxyimino cephalosporins","volume":"39","author":"Jett","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306025457_CIT0032","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.diagmicrobio.2003.11.007","article-title":"In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae","volume":"49","author":"Burgess","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20180306025457_CIT0033","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1128\/AAC.48.6.1941-1947.2004","article-title":"Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula","volume":"48","author":"Maglio","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306025457_CIT0034","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0732-8893(95)00053-D","article-title":"Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins","volume":"22","author":"Craig","year":"1995","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20180306025457_CIT0035","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ijantimicag.2005.06.004","article-title":"Pharmacodynamics of intermittent and continuous infusion piperacillin\/tazobactam and cefepime against extended-spectrum beta-lactamase-producing organisms","volume":"26","author":"Reese","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20180306025457_CIT0036","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/jac\/dkl349","article-title":"Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units","volume":"58","author":"Roos","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180306025457_CIT0037","volume-title":"Interscience Conference on Antimicrobial Agents and Chemotherapy","author":"Andes","year":"2001"},{"key":"key\n\t\t\t\t20180306025457_CIT0038","doi-asserted-by":"crossref","first-page":"ofw132","DOI":"10.1093\/ofid\/ofw132","article-title":"Cefepime therapy for cefepime-susceptible extended-spectrum \u03b2-lactamase\u2013producing Enterobacteriaceae bacteremia","volume":"3","author":"Wang","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"key\n\t\t\t\t20180306025457_CIT0039","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1469-0691.2005.01290.x","article-title":"High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients","volume":"12","author":"Goethaert","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20180306025457_CIT0040","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1128\/AAC.05419-11","article-title":"Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-\u03b2-lactamase-producing Klebsiella pneumoniae and Escherichia coli","volume":"56","author":"Chopra","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306025457_CIT0041","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1128\/AAC.47.11.3442-3447.2003","article-title":"Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study","volume":"47","author":"Zanetti","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306025457_CIT0042","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/cid\/cis916","article-title":"Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters","volume":"56","author":"Lee","year":"2013","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180306025457_CIT0043","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1086\/666632","article-title":"Extended-spectrum \u03b2-lactamase producers reported as susceptible to piperacillin-tazobactam, cefepime, and cefuroxime in the era of lowered breakpoints and no confirmatory tests","volume":"33","author":"Marchaim","year":"2012","journal-title":"Infect Control Hosp Epidemiol"},{"key":"key\n\t\t\t\t20180306025457_CIT0044","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1128\/AAC.38.11.2663","article-title":"In vivo efficacies of beta-lactam-beta-lactamase inhibitor combinations against a TEM-26-producing strain of Klebsiella pneumoniae","volume":"38","author":"Rice","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306025457_CIT0045","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1469-0691.2009.02893.x","article-title":"Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates","volume":"16","author":"L\u00f3pez-Cerero","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20180306025457_CIT0046","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1128\/AAC.00218-06","article-title":"Endocarditis caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility","volume":"50","author":"Zimhony","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306025457_CIT0047","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/cid\/cir790","article-title":"\u03b2-Lactam\/\u03b2-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum \u03b2-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts","volume":"54","author":"Rodriguez-Ba\u00f1o","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180306025457_CIT0048","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1128\/AAC.00381-05","article-title":"Clinical correlation of the CLSI susceptibility breakpoint for piperacillin-tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species","volume":"50","author":"Gavin","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306025457_CIT0049","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jinf.2012.01.008","article-title":"Piperacillin-tazobactam as an initial empirical therapy of bacteremia caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae","volume":"64","author":"Kang","year":"2012","journal-title":"J Infect"},{"key":"key\n\t\t\t\t20180306025457_CIT0050","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13756-015-0055-6","article-title":"Comparable outcomes for \u03b2-lactam\/\u03b2-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae","volume":"4","author":"Harris","year":"2015","journal-title":"Antimicrob Resist Infect Control"},{"key":"key\n\t\t\t\t20180306025457_CIT0051","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/cid\/civ003","article-title":"Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum \u03b2-lactamase bacteremia","volume":"60","author":"Tamma","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180306025457_CIT0052","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1128\/AAC.00365-16","article-title":"A multinational, preregistered cohort study of \u03b2-lactam\/\u03b2-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-\u03b2-lactamase-producing Enterobacteriaceae","volume":"60","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306025457_CIT0053","doi-asserted-by":"crossref","first-page":"e0153696","DOI":"10.1371\/journal.pone.0153696","article-title":"Empiric piperacillin-tazobactam versus carbapenems in the treatment of bacteraemia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae","volume":"11","author":"Ng","year":"2016","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180306025457_CIT0054","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13063-014-0541-9","article-title":"Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial","volume":"16","author":"Harris","year":"2015","journal-title":"Trials"},{"key":"key\n\t\t\t\t20180306025457_CIT0055","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1592\/phco.27.11.1490","article-title":"Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?","volume":"27","author":"Kim","year":"2007","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t20180306025457_CIT0056","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1128\/AAC.01802-13","article-title":"Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011\u20132012)","volume":"57","author":"Farrell","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306025457_CIT0057","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jinf.2014.04.004","article-title":"Ceftolozane\/tazobactam activity tested against aerobic gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012)","volume":"69","author":"Sader","year":"2014","journal-title":"J Infect"},{"key":"key\n\t\t\t\t20180306025457_CIT0058","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1128\/AAC.00049-14","article-title":"Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections","volume":"58","author":"Lucasti","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306025457_CIT0059","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180306025457_CIT0060","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1128\/AAC.02429-13","article-title":"Antimicrobial activity of ceftazidime-avibactam against gram-negative organisms collected from U.S. medical centers in 2012","volume":"58","author":"Sader","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306025457_CIT0061","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/jac\/dks523","article-title":"Comparative study of the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial","volume":"68","author":"Lucasti","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180306025457_CIT0062","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180306025457_CIT0063","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/64\/7\/972\/24254903\/cix034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T17:39:53Z","timestamp":1749922793000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/64\/7\/972\/2957271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,25]]},"references-count":63,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,1,25]]},"published-print":{"date-parts":[[2017,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/cix034","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727464249.793549919","asserted-by":"object"}]},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,4,1]]},"published":{"date-parts":[[2017,1,25]]}}}